Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Mycoses 1Mucormycosis 1Genetic Predisposition to Disease 1Candidiasis 1Breast Neoplasms 1Aspergillosis 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Surveys and Questionnaires 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × posaconazole × Clear all
NCT06541067 2026-01-26

POSALLO

Nantes University Hospital

Phase 2 Recruiting
30 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT07185503 2025-09-22

Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Institute of Hematology & Blood Diseases Hospital, China

Recruiting
60 enrolled
Other hematologic neoplasm

Mucormycosis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡